Electronic portfolios can be used to record user performance and achievements. Currently, clinical learning systems and in-service education systems lack integration of nurses' clinical performance records with their education or training outcomes. For nurses with less than 2 years' work experience (nursing postgraduate year), use of an electronic portfolio is essential. This study aimed to assess the requirements of using electronic portfolios in continuing nursing education for clinical practices. Fifteen nurses were recruited using a qualitative purposive sampling approach between April 2013 and May 2013. After obtaining participants' consent, data were collected in a conference room of the study hospital by one-on-one semistructured in-depth interviews. Through data analyses, the following five main themes related to electronic learning portfolios were identified: instant access to in-service education information, computerized nursing postgraduate year training manual, diversity of system functions and interface designs, need for sufficient computers, and protection of personal documents. Because electronic portfolios are beginning to be used in clinical settings, a well-designed education information system not only can meet the needs of nurses but also can facilitate their learning progress.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CIN.0000000000000112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implantable Cardioverter-Defibrillators and Cardiovascular Resynchronization Therapy with Left Ventricular Assist Devices: A MOMENTUM 3 Trial Analysis.
J Card Fail
January 2025
Columbia University Irving Medical Center, New York, NY. Electronic address:
Background: The benefit of implantable cardioverter-defibrillators (ICD) and cardiovascular resynchronization therapy (CRT-D) in patients supported with a HeartMate 3 left ventricular assist device (LVAD) remains uncertain.
Methods: An analysis of the MOMENTUM 3 randomized clinical trial and the first 1000 patients in the Continued Access Protocol trial. Patients were divided into three groups based on the presence of ICD and/or CRT-D: No device (n=153, 11%), ICD only (n=699, 50.
Philanthropic drug development: understanding its importance, mechanisms, and future prospects.
Drug Discov Today
January 2025
University Witten/Herdecke, 58455 Witten, Germany; DEBRA Research gGmbH, 80336 Munich, Germany; Knowledge House GmbH, 40213 Düsseldorf, Germany. Electronic address:
Philanthropic drug development (PDD) addresses gaps in traditional pharmaceutical innovation, particularly for rare and underserved diseases. Cost and timeline challenges discourage new investments, especially in niche therapeutic areas. Patient organizations (POs) are uniquely positioned to help to reduce development challenges by providing expertise, supporting early research, fostering collaborations, and driving patient-centered clinical trials.
View Article and Find Full Text PDFUse of an electronic portfolio for longitudinal assessment of personal and professional development in undergraduate medical education.
Front Med (Lausanne)
January 2025
Department of Medical Education, Geisinger College of Health Sciences, Scranton, PA, United States.
Dynamic linkages and spillover effects of biodiversity risk in socially responsible investment and commodity markets.
J Environ Manage
January 2025
Institute of Policy Studies, Universiti Brunei Darussalam, Jalan Tungku Link, BE1410, Brunei Darussalam; Crawford School of Public Policy, Australian National University, ACT 2600, Australia.
This study employs a novel biodiversity risk measure, developed through textual analysis, to examine how biodiversity risk affects socially responsible investment (SRI) and commodity markets. Biodiversity-related financial risks, arising from ecosystem degradation, represent an emerging and underexplored dimension of market risk, particularly for investors seeking sustainability-aligned portfolios. Our analysis reveals that both SRI equity and commodity indices consistently exhibit negative time-varying correlations with biodiversity risk, with correlations as low as -0.
View Article and Find Full Text PDFDevelopment of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!